Market Strategy - The market is experiencing a rebound after hitting a low, with a notable recovery in the storage chip sector [5][7] - The overall A-share market saw a slight decline of 0.05%, with the Shanghai Composite Index down 0.26% and the ChiNext Index up 1.41% [7][8] - The storage chip sector is leading the market rebound, supported by anticipated price increases in storage products by major companies like Samsung and SK Hynix [10] Economic Indicators - In January-February 2026, the total retail sales of consumer goods in China reached 86,079 billion yuan, a year-on-year increase of 2.8% [15][16] - The industrial added value for large-scale enterprises grew by 6.3% year-on-year during the same period, with manufacturing increasing by 6.6% [17][18] - Fixed asset investment (excluding rural households) was 52,721 billion yuan, reflecting a year-on-year growth of 1.8% [19][20] Industry Dynamics - The real estate market saw new home sales of 818.6 billion yuan in January-February 2026, a year-on-year decline of 20.2% [27][28] - The National Bureau of Statistics reported that the sales prices of commercial residential properties in 70 large and medium-sized cities continued to narrow their decline in February 2026 [29][30] - The Southern Power Grid Company reported a significant increase in fixed asset investment, reaching 250.8 billion yuan in the first two months of 2026, a year-on-year growth of 95.3% [31][32] Company Updates - Haishi Ke (002653.SZ) received approval for clinical trials of its innovative drug HSK46575 for new indications in prostate cancer treatment [40][41] - Shantui (000680.SZ) reported a 2.82% increase in revenue for 2025, with net profit rising by 9.86% year-on-year, driven by strong performance in overseas markets [42][43]

Market Overview - The A-share pharmaceutical and biotechnology index increased by 0.50% last week, underperforming the CSI 300 index by 0.58 percentage points and the ChiNext index by 1.82 percentage points, ranking 25th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index fell by 6.07%, underperforming the Hang Seng Index by 4.96 percentage points [4] R&D Progress - Last week, several clinical applications were newly undertaken, including CMS-D008 injection by Kangzhe Pharmaceutical and KC1036 tablets by Kangchen Pharmaceutical [4] - Other IND applications included HSK46575 tablets by Haishi Pharmaceutical, injection of Lankangyilong monoclonal antibody by Bailitianheng, and injection of BL-M11D1 [4] - Notable ongoing clinical trials include ICP-538 by Nocera Biopharma and DC6001 by China Resources Sanjiu in Phase I, HLX43 by Fuhong Hanlin and Punanli monoclonal antibody by Tianjing Biopharma in Phase II, and SYH2053 and SYS6010 by Shiyao Group in Phase III [4] Investment Outlook - The company maintains a positive outlook on the pharmaceutical sector's recovery, reiterating the investment thesis based on the three stages of clinical value: 1. "0→1" technological breakthroughs in innovative drugs, particularly in oncology, weight loss, and autoimmune diseases, as well as advancements in innovative medical devices like brain-machine interfaces [5] 2. "1→10" clinical validation with high-quality domestic innovative drugs accelerating overseas authorization and the rise of high-end medical devices [5] 3. "10→100" efficiency in China, where CXO companies leverage low costs and high efficiency to build competitive advantages, particularly in the disposable medical supplies sector [5] - The focus is on the accelerated overseas expansion of innovative drugs and their upstream CXO, as well as the innovation and upgrade of high-end medical devices and high-value consumables [5]

Core Viewpoint - Company subsidiary, Liaoning Hisun Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the clinical trial application of drug "HSK46575" in combination with Olaparib or Docetaxel and Prednisone for the treatment of prostate cancer [1] Group 1: Drug Development - HSK46575 is a self-developed oral, potent, and highly selective small molecule inhibitor intended for prostate cancer treatment [1] - Preclinical research results indicate that the drug has a clear target, definite efficacy, and good safety profile, showcasing significant development potential [1] - The drug is expected to become an effective treatment for prostate cancer, addressing the current shortage of clinical treatment options [1] Group 2: Regulatory Classification - According to the National Medical Products Administration's announcement on the classification and application requirements for chemical drug registration, HSK46575 is classified as a Class 1 chemical drug [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Liaoning Hisun Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the clinical trial application of the drug "HSK46575" in combination with Olaparib or Docetaxel and Prednisone for the treatment of prostate cancer [1] Group 1: Drug Development - HSK46575 is a self-developed oral, potent, and highly selective small molecule inhibitor intended for the treatment of prostate cancer [1] - Preclinical research results show that the drug has a clear target, definite efficacy, and good safety profile, indicating high development potential [1] - The drug is expected to become an effective treatment for prostate cancer, addressing the current shortage of clinical treatment options [1] Group 2: Regulatory Classification - According to the National Medical Products Administration's announcement regarding the classification and application requirements for chemical drug registration, HSK46575 is classified as a Class 1 chemical drug [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Liaoning Hisun Pharmaceutical Co., Ltd., has received a clinical trial application acceptance notice from the National Medical Products Administration for HSK46575 tablets in combination with Olaparib or Docetaxel and Prednisone for the treatment of prostate cancer [1] Group 1 - HSK46575 is a self-developed oral, potent, and highly selective small molecule inhibitor intended for prostate cancer treatment [1] - Preclinical research results show that HSK46575 has a clear target, definite efficacy, and good safety, indicating a broad clinical application prospect [1]

Core Viewpoint - Company Haisco (002653.SZ) has received an acceptance notice from the National Medical Products Administration for its drug HSK46575, which is a small molecule inhibitor developed for the treatment of prostate cancer [1] Group 1: Drug Development - HSK46575 is an orally administered, potent, and highly selective small molecule inhibitor [1] - Preclinical research indicates that the drug has a clear target, definite efficacy, and good safety profile, showcasing its significant development potential [1] - The drug is expected to address the current shortage of effective treatments for prostate cancer, presenting a high benefit/risk ratio for clinical application [1]